Ilya Pharma AB

Delivering local immunotherapies to patients

In press


Ilya Pharma

Ilya Pharma, being a clinical stage biopharmaceutical development company is currently pursuing three clinical programs drug candidates from its proprietary ILP-technology platform.

The research is inspired by the early work of Professor Ilya Mechnicov who also received the Nobel Prize in 1908, describing immune cells have multiple function in vivo, read more here.



Drug Development

Well known, biochemically instable, human therapeutic proteins are produced at the actual affected by live lactic acid bacteria acting as local mini-bioreactors. This provides a new and cost-effective way to deliver therapeutic proteins and enables development of a wide range of immunomodulatory proteins that are not suited to be developed as biologics. 

The drug candidates are classified as ATMP and gene therapies by the EMA and FDA.



The innovation now, being a validated ILP-technology platform, originally stems from cutting edge medical research in immunophysiology and applied microbiology at Uppsala University and the Swedish University of Agricultural Sciences. The different ILP-drug candidates uses the function of tissue-resident immune cells in different organs to treat disease and the ILP-candidates are local-acting immunotherapies. 



Clinical development

Unmet clinical needs targeted are diseases in skin and mucosal surfaces.

ILP100-Topical:A first-in-human clinical trial (WHILYAS1, EudraCT No. 2019000680-24) have been successfully completed and reported. 

An IND for a pivotal adaptive phase 2 clinical trial in treatment of wound following breast surgery have been granted and patients with pre-diabetes, diabetes and obesity having weeks to months longer healing time and increased complications, will be included. 

A phase IIa study (WHILYAS2) in patients with diabetes and chronic wounds, funded by the EIC Accelerator is approved ans first dosing is expected in 2021.

ILP100-Oral: 30-40% of cancer patients receiving treatment witch checkpoint inhibitors (aPD1, aPDL1, aCTLA-4) have to discontinues treatment due to severe colitis developed as an immune related adverse event (irAE). The company are currently performing IND-enabling studies and expect to be able to start a first clinical trial in patients with ICI-induced colitis in 12-18 months.  



Ilya Pharma is today financed by a mix of grants and private funding. The company received a H2020 SME Instrument phase II grant 2018 of 3 MEUR and EIC Accelerator 2020 of 5.3 MEUR. The company is currently raising for the continued clinical development in phase IIs and IND enabling studies in ICI-induced colitis from suitable investors and potential partners with proven track record in cell- and gene therapy and therapeutics. 




Evelina Vågesjö


Mia Phillipson


Peter Frank

PMO and Head of QA

Ingemar Kihlström

Chairman of the Board

Andreas Fasth

Head of Clinical Developments and Medical Affairs

Lovisa Ringstad

Head of CMC

Stefan Roos


Margareth Jorvid

Head of Regulatory Affairs

Oskar Lund




Contact Us

Ilya Pharma AB, Uppsala, Sweden

Evelina Vågesjö, CEO
+46 (0)70 636 64 94